Zydus gets rights to re-launch, manufacture Microbix's urokinase
This article was originally published in Scrip
Executive Summary
The Canadian firm, Microbix Biosystems, has licensed all rights and expertise concerning its thrombolytic drug, Kinlytic (urokinase), to Zydus Cadila under a milestone-cum-royalty-based pact that aims to reintroduce the product in North America.